RESUMO
Pregnancy with chronic kidney disease is challenging, and patients with diabetic nephropathy are at particular risk of a rapid kidney function decline during pregnancy. While indications for the management of pregnant patients with initial diabetic nephropathy are widely available in the literature, data on patients with severe nephrotic syndrome and kidney function impairment are lacking, and the decision on whether and when dialysis should be initiated is not univocal. We report a type 1 diabetes patient who started pregnancy with a severe nephrotic syndrome and shifted from CKD stage 3b to stage 5 during pregnancy. The management was complicated by a fetal heart malformation and by poorly controlled diabetes. The evidence for and against starting dialysis was carefully evaluated, and the choice of strict nephrological and obstetrical monitoring, nutritional management, and diuretic treatment made it possible to avoid dialysis in pregnancy, after ruling out pre-eclampsia. This experience enables examination of some open issues and contributes to the discussion of when to start dialysis in pregnancy.
Assuntos
Leucemia-Linfoma Linfoblástico de Células Precursoras/epidemiologia , Pele/patologia , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Antígenos de Neoplasias/análise , Criança , Pré-Escolar , Feminino , Humanos , Imunofenotipagem , Lactente , Recém-Nascido , Estimativa de Kaplan-Meier , Infiltração Leucêmica , Masculino , Pessoa de Meia-Idade , Leucemia-Linfoma Linfoblástico de Células Precursoras/patologia , Leucemia-Linfoma Linfoblástico de Células Precursoras/terapia , Prognóstico , Modelos de Riscos Proporcionais , Estudos Retrospectivos , Resultado do Tratamento , Adulto JovemAssuntos
Predisposição Genética para Doença , Receptor Celular 2 do Vírus da Hepatite A/genética , Linfo-Histiocitose Hemofagocítica/diagnóstico , Linfo-Histiocitose Hemofagocítica/genética , Linfoma de Células T/diagnóstico , Linfoma de Células T/genética , Mutação , Paniculite/diagnóstico , Paniculite/genética , Biomarcadores , Feminino , Estudos de Associação Genética , Humanos , MasculinoRESUMO
Hypocomplementemic urticarial vasculitis is a rare systemic vasculitis, affecting small vessels, characterised by chronicle urticaria, hypocomplementemia, and systemic manifestations. Renal involvement, whose prevalence varies between 9% and 60%, is mainly glomerular. We here report the case of a 59 years old woman presenting kidney failure, associated with chronicle urticaria and arthralgias. Laboratory investigation showed haematuria, proteinuria, hypocomplementemia and anti-SSa antibody positivity. A percutaneous kidney biopsy revealed focal and segmental glomerulonephritis associated with an acute interstitial nephritis. Hypocomplementemic urticarial vasculitis diagnosis was established after identifying anti-C1q antibodies. The lack of a dry syndrome, the negativity of a Schirmer test and the lack of sialadenitis on a salivary gland biopsy excluded an associated Gougerot-Sjögren Syndrome. The patient was treated with hydroxychloroquine and low-dose steroids, enabling a clinical and biological recovery. Of the 82 cases in the literature describing hypocomplementemic urticarial vasculitis associated nephropathies, 72 (88%) were a glomerular impairment, most frequently secondary to membranoproliferative glomerulonephritis. Only 6 (7%) tubulo-interstitial nephritis have been reported, 4 of them being associated with a glomerulonephritis. Patients were more likely to be women, aged in their third decade. The most frequent renal manifestations were haematuria (60%), and proteinuria (52%). Kidney failure was rarely observed (22%), with a fairly good renal prognosis. Hypocomplementemic urticarial vasculitis was associated with a systemic disease in 11 (13%) patients. In the absence of recommendations, the treatment strategy remains to be defined.
Assuntos
Complemento C1/deficiência , Glomerulonefrite Membranoproliferativa/complicações , Nefrite Intersticial/complicações , Urticária/complicações , Vasculite/complicações , Feminino , Humanos , Pessoa de Meia-IdadeRESUMO
BACKGROUND: Immune checkpoint inhibitor (ICI)-associated early cardiac adverse events (CAEs), mostly acute and fulminant myocarditis, have been well characterized and mainly occur during the first 90 days after ICI therapy initiation. ICI-associated late CAEs (occurring after the first 90 days of treatment) have not yet been described. METHODS: First, we compared characteristics of a cohort involving early (defined as a CAE time to onset (TTO) of <90 days after ICI therapy initiation) and late (defined as a CAE TTO of ≥90 days after ICI therapy initiation) ICI-associated CAE consecutive cases who were referred to three French cardio-oncology units. Second, ICI-associated CAE cases were searched in VigiBase, the WHO global individual case safety report database, and early and late ICI-associated CAEs were compared. RESULTS: In the cohort study, compared with early CAE cases (n=19, median TTO of 14 days), late ICI-associated CAE cases (n=19, median TTO of 304 days) exhibited significantly more left ventricular systolic dysfunction (LVSD) and heart failure (HF) and less frequent supraventricular arrhythmias. In VigiBase, compared with early cases (n=437, 73.3%, median TTO 21 days), the late ICI-associated CAE reports (n=159, 26.7%, median TTO 178 days) had significantly more frequent HF (21.1% vs 31.4%, respectively, p=0.01). Early and late ICI-associated CAE cases had similarly high mortality rates (40.0% vs 44.4% in the cohort and 30.0% vs 27.0% in VigiBase, respectively). CONCLUSIONS: Late CAEs could occur with ICI therapy and were mainly revealed to be HF with LVSD. TRIAL REGISTRATION NUMBERS: NCT03678337, NCT03882580, and NCT03492528.
Assuntos
Antineoplásicos Imunológicos/efeitos adversos , Cardiotoxicidade/etiologia , Imunoterapia/efeitos adversos , Miocardite/induzido quimicamente , Neoplasias/tratamento farmacológico , Idoso , Anticorpos Monoclonais Humanizados/administração & dosagem , Antineoplásicos Imunológicos/uso terapêutico , Cardiotoxicidade/patologia , Feminino , Humanos , Ipilimumab/administração & dosagem , Masculino , Miocardite/patologia , Neoplasias/imunologia , Nivolumabe/administração & dosagem , Estudos RetrospectivosRESUMO
BACKGROUND: Histological evaluation of malignant hematologic involvement of the skin can be challenging and needs an extended immunohistochemistry panel. We assessed the ability of flow cytometry (FCM) to detect neoplastic cell subsets in skin biopsies as a useful tool that supplements the histological examination in a complementary way. METHODS: Two hundred and forty-three consecutive skin biopsies were retrospectively analyzed between April 2012 and July 2017. RESULTS: Among them, 147 samples, corresponding to 128 patients, were analyzed at diagnosis. Eighty-seven patients had erythrodermic inflammatory dermatoses, and 41 patients had cutaneous hematologic neoplasms. Cutaneous T-cell lymphomas were the most frequent disorders, accounting for 70% of cases (29/41). Cutaneous B-cell lymphoma was found in only 17% of cases (7/41) and immature hematologic malignancies in 5% (2/41). Three patients had secondary skin involvement. The sensitivity of FCM skin biopsy analysis was 78.1% (32/41). Among the 243 samples, 27 patients had mycosis fungoides (MF) or Sezary syndrome (SS) with available FCM data. A loss of CD26 expression was identified in 92% of cases of transformed MF or SS versus 40% of cases of non-transformed MF (P = 0.0057 χ²). Among the 12 MF patients with negative CD26 expression, six progressed to SS versus none in the positive group (50% vs. 0% P = 0.0168 χ²). CONCLUSIONS: FCM analysis of the skin biopsies is a sensitive method and a useful tool for improving the sensitivity of diagnosis of hematologic skin neoplasms. Among the MF patients, a loss of CD26 expression could be a marker of higher risk of progression. © 2019 International Clinical Cytometry Society.
Assuntos
Citometria de Fluxo , Neoplasias Hematológicas/diagnóstico , Transtornos Mieloproliferativos/diagnóstico , Neoplasias Cutâneas/diagnóstico , Idoso , Estudos de Coortes , Dipeptidil Peptidase 4/genética , Feminino , Neoplasias Hematológicas/genética , Humanos , Masculino , Pessoa de Meia-Idade , Transtornos Mieloproliferativos/genética , Neoplasias Cutâneas/genéticaRESUMO
A 35 year old woman with chronic pelvic endometriosis suffered from right scapular pain. MRI imaging showed a right diaphragmatic rupture with liver herniation. Surgical procedure was performed by thoracotomy. The liver was put back into the abdomen, endometriosis was resected from the diaphragm, interrupted non absorbable suture of the diaphragm was performed and an absorbable mesh was placed. Endometriosis was confirmed on histological analysis of the resected diaphragm. To study this pathology, we performed a systematic review of the literature and found 12 similar cases of diaphragmatic rupture due to endometriosis. Right diaphragm is often involved and rupture is always located on the tendinous portion. Symptoms are mainly cyclic right scapular pain and cathamenial pneumothorax. MRI should be performed in case of suggestive symptoms and a systematic exploration of the diaphragm should be performed at laparoscopy for an early treatment of the lesions to prevent progression to rupture.
Assuntos
Diafragma/lesões , Endometriose/complicações , Hérnia Diafragmática/etiologia , Fígado/cirurgia , Adulto , Diafragma/diagnóstico por imagem , Diafragma/cirurgia , Endometriose/diagnóstico por imagem , Endometriose/cirurgia , Feminino , Hérnia Diafragmática/diagnóstico por imagem , Hérnia Diafragmática/cirurgia , Humanos , Imageamento por Ressonância Magnética , Ruptura , ToracotomiaRESUMO
AIMS: We applied the 2017 World Health Organization (WHO) classification criteria to categorise a series of 64 primary cutaneous large B-cell lymphomas (PCLBCLs), containing a majority (≥80%) of large cells and a proliferative rate of ≥40%, raising the problem of the differential diagnosis between PCLBCL, leg type (PCLBCL-LT) and primary cutaneous follicle centre lymphoma, large cell (PCFCL-LC). The aims were to determine the reproducibility and prognostic relevance of the 2017 WHO criteria. METHODS AND RESULTS: Morphology and phenotype identified 32 PCLBCLs-LT and 25 PCFCLs-LC; seven cases (11%) remained unclassified. Morphology was less reproducible than immunophenotype. Pertinent markers for the differential diagnosis were MUM1, FOXP1, CD10, and IgM. bcl-2 and bcl-6 were expressed by both PCFCLs-LC and PCLBCLs-LT at substantial levels. Neither Ki67 expression nor p63 expression was of diagnostic value. MYD88 was found to be mutated only in PCLBCLs-LT (n = 22, 69%). According to Hans/Hans modified algorithms, 23 of 25 PCFCLs-LC had germinal centre (GC) status, and the 32 PCLBCLs-LT had non-GC status. Overall survival was poorer for PCLBCLs-LT than PCFCLs-LC (P = 0.0002). Non-GC cases had poorer overall survival than GC cases (P = 0.0007). In PCLBCLs-LT, MYC expression was associated with cutaneous relapses (P = 0.014). When GC/non-GC status was applied to unclassified cases, only a single case remained discordant. CONCLUSIONS: Our results support the 2017 WHO classification criteria for PCLBCL diagnosis. The Hans modified algorithm using CD10 and MUM1 distinguished PCFCLs-LC from PCLBCLs-LT with optimal diagnostic value without requiring bcl-6 immunolabelling (poorly reproducible). Rare unclassified cases may constitute a provisionally heterogeneous subgroup for which GC/non-GC status (relevant for prognosis) may guide therapeutic decisions.
Assuntos
Biomarcadores Tumorais/análise , Linfoma de Células B/classificação , Linfoma Folicular/classificação , Neoplasias Cutâneas/classificação , Adulto , Idoso , Idoso de 80 Anos ou mais , Diagnóstico Diferencial , Feminino , Centro Germinativo/patologia , Humanos , Imunofenotipagem , Linfoma de Células B/diagnóstico , Linfoma de Células B/patologia , Linfoma Folicular/diagnóstico , Linfoma Folicular/patologia , Masculino , Pessoa de Meia-Idade , Prognóstico , Reprodutibilidade dos Testes , Pele/patologia , Neoplasias Cutâneas/diagnóstico , Neoplasias Cutâneas/patologia , Organização Mundial da SaúdeRESUMO
B-cell clones can produce a monoclonal immunoglobulin, which may be responsible for visceral involvements. Kidney involvement is frequent, affecting 20 to 50% of patients with multiple myeloma. One mechanism underlying this involvement is a dysregulation of the complement alternative pathway, leading to C3 glomerulopathies. We report a patient who had a multiple myeloma, C3 glomerulopathy related to factor H autoantibody, and digital ischemia, who was treated successfully with eculizumab, an anti-complement therapy, without any relapse in 2 years of follow-up.
Assuntos
Anticorpos Monoclonais Humanizados/uso terapêutico , Complemento C3/imunologia , Fator H do Complemento/imunologia , Glomerulonefrite/tratamento farmacológico , Isquemia/tratamento farmacológico , Idoso , Autoanticorpos , Feminino , Glomerulonefrite/imunologia , Humanos , Isquemia/imunologiaAssuntos
Adenocarcinoma/complicações , Neoplasias do Colo/complicações , Neoplasias do Colo/diagnóstico , Lúpus Eritematoso Cutâneo/patologia , Adenocarcinoma/diagnóstico , Adenocarcinoma/cirurgia , Idoso , Biópsia por Agulha , Neoplasias do Colo/cirurgia , Progressão da Doença , Detecção Precoce de Câncer , Evolução Fatal , Humanos , Imuno-Histoquímica , Lúpus Eritematoso Cutâneo/diagnóstico , Imageamento por Ressonância Magnética/métodos , Masculino , Invasividade Neoplásica/patologia , Estadiamento de Neoplasias , Doenças Raras , Medição de Risco , Tomografia Computadorizada por Raios X/métodos , Ultrassonografia Doppler/métodosRESUMO
Bile cast nephropathy is a tubulo-interstitial nephropathy. Its diagnosis may be under-estimated. It develops in patients who have cholestatic jaundice, with high bilirubinemia. Bile salts are freely filtered through glomerulus. Under certain circumstances, it forms casts into the tubule and cause an acute tubular necrosis. The diagnosis evidence is histologic, but fulfilment of renal biopsy is often made difficult, because of the hemostatic abnormalities that patients with hepatocellular injury develop. The treatment is supportive and etiological. We report here the case of a patient who presented a drug-induced hepatic jaundice, complicated with acute kidney failure secondary to bile cast nephropathy. We present the histological diagnosis evidence.
Assuntos
Icterícia Obstrutiva/diagnóstico , Icterícia Obstrutiva/terapia , Nefrose/diagnóstico , Nefrose/terapia , Diálise Renal , Injúria Renal Aguda/diagnóstico , Injúria Renal Aguda/terapia , Idoso , Antioxidantes/metabolismo , Ácidos e Sais Biliares/metabolismo , Bilirrubina/sangue , Biomarcadores/sangue , Biópsia , Fármacos Gastrointestinais/metabolismo , Humanos , Icterícia Obstrutiva/sangue , Icterícia Obstrutiva/induzido quimicamente , Túbulos Renais/efeitos dos fármacos , Túbulos Renais/patologia , Masculino , Necrose , Nefrose/sangue , Nefrose/induzido quimicamente , Diálise Renal/métodos , Fatores de Risco , Resultado do TratamentoAssuntos
Biomarcadores Tumorais/genética , Linfoma Folicular/genética , Linfoma Difuso de Grandes Células B/genética , Fator 88 de Diferenciação Mieloide/genética , Neoplasias Cutâneas/genética , Idoso de 80 Anos ou mais , Diagnóstico Diferencial , Feminino , Humanos , Linfoma Folicular/diagnóstico , Linfoma Difuso de Grandes Células B/diagnóstico , Masculino , Pessoa de Meia-Idade , Mutação , Análise de Sequência de DNA , Neoplasias Cutâneas/diagnósticoAssuntos
Neoplasias Pulmonares/secundário , Síndrome de Sézary/patologia , Neoplasias Cutâneas/patologia , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Biópsia por Agulha , Progressão da Doença , Evolução Fatal , Humanos , Imuno-Histoquímica , Neoplasias Pulmonares/tratamento farmacológico , Neoplasias Pulmonares/patologia , Masculino , Pessoa de Meia-Idade , Invasividade Neoplásica/patologia , Estadiamento de Neoplasias , Medição de Risco , Síndrome de Sézary/diagnóstico , Síndrome de Sézary/tratamento farmacológico , Neoplasias Cutâneas/diagnóstico , Neoplasias Cutâneas/tratamento farmacológicoRESUMO
INTRODUCTION: Vasculitides occurring during parasitic infection are rare and may imply different mechanisms. METHODS: A case report of cutaneous vasculitis and visceral damage during a larva migrans syndrome. RESULTS: We report the case of a 64-year-old man who developed a purpura along with fever, respiratory failure, abdominal pain and myalgia. Immunological screening showed a high titer of both antinuclear antibodies and anti-double-stranded DNA antibodies along with anti-C1q antibodies. Toxocara canis serology returned highly positive with a positive western-blot. The use of antiparasitic drugs in combination with corticosteroids resulted in a dramatic improvement in the patient's condition. CONCLUSIONS: Clinicians should be aware of the systemic complications that may occur during Toxocara canis infection, including vasculitis and immunological disorder.
Assuntos
Autoanticorpos/imunologia , Complemento C1q/imunologia , Toxocara canis/imunologia , Toxocaríase/complicações , Vasculite/diagnóstico , Vasculite/patologia , Animais , Antiparasitários/uso terapêutico , Humanos , Imunossupressores/uso terapêutico , Masculino , Pessoa de Meia-Idade , Resultado do TratamentoRESUMO
PURPOSE: Overexpression of hypoxia inducible factor-1 α (HIF-1α) has been found in several cancers and is thought to correlate with aggressive disease. The purpose of our study was to investigate the influence of HIF-1α on clinical outcome in uveal melanoma (UM) along with proliferative (MIB-1) and vascular (CD31, VEGF-A) markers. METHODS: A retrospective analysis was carried out on UM tumors from 88 patients. HIF-1α, MIB-1, CD31, and VEGF-A expression, as well as necrosis, were assessed by immunohistochemistry and hematoxylin/eosin on paraffin-embedded UM tumor sections by using a tissue microarray. The bivariate analysis involving HIF-1α expression and clinicopathologic covariates was performed by using the χ(2) test. The association of clinicopathologic covariates and HIF-1α expression with patient survival was evaluated by using the Kaplan-Meier approach and Cox proportional-hazards regression analysis. RESULTS: Among our study population, 56 patients (63.6%) had high levels of HIF-1α expression. High expression of HIF-1α was associated with high expression of MIB-1 (P = 0.04), CD31 (P = 0.03), and VEGF-A (P < 0.0001), as well as necrosis (P = 0.04). However, high HIF-1α expression was not correlated with cell type, largest macroscopic tumor dimension or thickness, anterior margin, pigmentation, or mitotic figures. Patients with high HIF-1α expression did not show a reduced survival when compared to patients with low HIF-1α expression (P = 0.92). Finally, HIF-1α expression was not increased after irradiation. CONCLUSIONS: An increase in HIF-1α expression was significantly associated with proliferative (MIB-1) and vascular (CD31 and VEGF-A) markers, as well as necrosis, in UM. However, there was no correlation between high HIF-1α expression and patient survival.
Assuntos
Proliferação de Células , Subunidade alfa do Fator 1 Induzível por Hipóxia/biossíntese , Melanoma/metabolismo , Molécula-1 de Adesão Celular Endotelial a Plaquetas/metabolismo , Neoplasias Uveais/metabolismo , Fator A de Crescimento do Endotélio Vascular/metabolismo , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Biomarcadores Tumorais/metabolismo , Feminino , Humanos , Imuno-Histoquímica , Masculino , Melanoma/patologia , Pessoa de Meia-Idade , Prognóstico , Estudos Retrospectivos , Análise Serial de Tecidos , Neoplasias Uveais/patologia , Adulto JovemAssuntos
Antineoplásicos/uso terapêutico , Cladribina/uso terapêutico , Glomerulonefrite por IGA/complicações , Leucemia de Células Pilosas/tratamento farmacológico , Vasculite Leucocitoclástica Cutânea/complicações , Idoso , Diagnóstico Diferencial , Humanos , Leucemia de Células Pilosas/diagnóstico , Leucemia de Células Pilosas/etiologia , Masculino , Recidiva Local de NeoplasiaAssuntos
Neoplasias Pulmonares/diagnóstico , Neoplasias Pulmonares/secundário , Linfoma Cutâneo de Células T/diagnóstico , Micose Fungoide/patologia , Tomografia por Emissão de Pósitrons , Neoplasias Cutâneas/secundário , Tomografia Computadorizada por Raios X , Fluordesoxiglucose F18 , Humanos , Masculino , Pessoa de Meia-Idade , Imagem Multimodal , Compostos RadiofarmacêuticosRESUMO
We describe the main characteristics and treatment of urogenital manifestations in patients with Wegener granulomatosis (WG). We conducted a retrospective review of the charts of 11 patients with WG. All patients were men, and their median age at WG diagnosis was 53 years (range, 21-70 yr). Urogenital involvement was present at onset of WG in 9 cases (81%), it was the first clinical evidence of WG in 2 cases (18%), and was a symptom of WG relapse in 6 cases (54%). Symptomatic urogenital involvement included prostatitis (n = 4) (with suspicion of an abscess in 1 case), orchitis (n = 4), epididymitis (n = 1), a renal pseudotumor (n = 2), ureteral stenosis (n = 1), and penile ulceration (n = 1). Urogenital symptoms rapidly resolved after therapy with glucocorticoids and immunosuppressive agents. Several patients underwent a surgical procedure, either at the time of diagnosis (n = 3) (consisting of an open nephrectomy and radical prostatectomy for suspicion of carcinoma, suprapubic cystostomy for acute urinary retention), or during follow-up (n = 3) (consisting of ureteral double J stents for ureteral stenosis, and prostate transurethral resection because of dysuria). After a mean follow-up of 56 months, urogenital relapse occurred in 4 patients (36%). Urogenital involvement can be the first clinical evidence of WG. Some presentations, such as a renal or prostate mass that mimics cancer or an abscess, should be assessed to avoid unnecessary radical surgery. Urogenital symptoms can be promptly resolved with glucocorticoids and immunosuppressive agents. However, surgical procedures, such as prostatic transurethral resection, may be mandatory in patients with persistent symptoms.